leisure time -WSS

leisure time

author：hotspot 2025-09-30 23:45:29 - browse：2

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Fetal cell organoids grown from amniotic fluid, study finds

WSS

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

As H5N1 spreads in cows, experts warn against drinking raw milk

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Obesity drug from Roche shows promise in early study

The United States must get value

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

At least 13 dead in Texas as scorching temps continue

Florida health officials providing scant details on measles cases

Medical leaders decry Supreme Court decision on affirmative action

CVS is willing to dump 10% of its Medicare Advantage members

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Apple is now the first public company to be valued at $3 trillion

Change Healthcare: What is it, why does its cyberattack matter?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Obesity drug from Roche shows promise in early study

entertainment

IVF doctors demand details after CooperSurgical lawsuit

Free medical tuition alone isn't enough to close gaps in primary care

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

WuXi Biologics execs register to lobby as Congress comes for the company

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Obesity drug from Roche shows promise in early study

Wikipedia

Wikipedia

knowledge

knowledge